Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and. | April 17, 2023
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective reduced by Canaccord Genuity Group from $16.00 to $8.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price […]
Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Stock analysts at Cantor Fitzgerald upped their FY2023 earnings per share estimates for Harpoon Therapeutics in a report released on Wednesday, March 29th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earnings of ($1.11) per share for the year, up from their prior […]
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective trimmed by HC Wainwright from $7.00 to $4.50 in a report released on Wednesday morning, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Harpoon Therapeutics’ Q1 2023 earnings at ($0.52) EPS, Q2 2023 earnings […]